Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASXC Asensus Surgical	$0.35	$0.35	$0.17 ▼ $0.40	$94.74M	1.37	2.03 million shs	N/A
INO Inovio Pharmaceuticals	$1.95 +2.6%	$1.95	$1.42 ▼ $12.33	$71.51M	1.34	626,628 shs	560,050 shs
KRMD KORU Medical Systems	$3.25	$2.83	$1.86 ▼ $5.05	$149.96M	0.43	136,481 shs	233,621 shs
MGRM Monogram Orthopaedics	$2.93 +1.7%	$2.69	$1.92 ▼ $4.21	$104.57M	0.41	248,730 shs	102,386 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASXC Asensus Surgical	0.00%	0.00%	0.00%	0.00%	+41.08%
INO Inovio Pharmaceuticals	0.00%	-6.25%	-8.45%	+1.56%	-77.22%
KRMD KORU Medical Systems	0.00%	+1.56%	+10.17%	+15.66%	+45.74%
MGRM Monogram Orthopaedics	0.00%	+11.41%	+6.16%	-7.86%	+39.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASXC Asensus Surgical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	3.6802 of 5 stars	3.3	2.0	0.0	4.3	2.8	0.0	0.6
KRMD KORU Medical Systems	3.3517 of 5 stars	3.5	5.0	0.0	0.0	0.0	2.5	0.6
MGRM Monogram Orthopaedics	2.1854 of 5 stars	3.8	3.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASXC Asensus Surgical	0.00	N/A	N/A	N/A
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	400.00% Upside
KRMD KORU Medical Systems	3.00	Buy	$4.50	38.46% Upside
MGRM Monogram Orthopaedics	3.50	Strong Buy	$5.40	84.30% Upside

Current Analyst Ratings Breakdown

Latest ASXC, INO, MGRM, and KRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/8/2025	KRMD KORU Medical Systems	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.50 ➝ $3.50

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASXC Asensus Surgical	$8.58M	11.04	N/A	N/A	$0.13 per share	2.68
INO Inovio Pharmaceuticals	$220K	325.03	N/A	N/A	$1.90 per share	1.03
KRMD KORU Medical Systems	$33.65M	4.46	N/A	N/A	$0.37 per share	8.78
MGRM Monogram Orthopaedics	$370K	282.63	N/A	N/A	$0.42 per share	6.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASXC Asensus Surgical	-$78.43M	-$0.31	N/A	N/A	N/A	-902.25%	-184.10%	-114.75%	N/A
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
KRMD KORU Medical Systems	-$6.07M	-$0.11	N/A	N/A	N/A	-15.09%	-30.43%	-19.41%	8/6/2025 (Estimated)
MGRM Monogram Orthopaedics	-$16.33M	-$0.45	N/A	N/A	N/A	N/A	-115.71%	-92.75%	8/13/2025 (Estimated)

Latest ASXC, INO, MGRM, and KRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MGRM Monogram Orthopaedics	-$0.12	-$0.10	+$0.02	-$0.10	N/A	N/A
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/7/2025	Q1 2025	KRMD KORU Medical Systems	-$0.02	-$0.03	-$0.01	-$0.03	$8.86 million	$9.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASXC Asensus Surgical	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRMD KORU Medical Systems	N/A	N/A	N/A	N/A	N/A
MGRM Monogram Orthopaedics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASXC Asensus Surgical	N/A	1.00	0.69
INO Inovio Pharmaceuticals	N/A	2.63	2.63
KRMD KORU Medical Systems	0.01	2.44	2.02
MGRM Monogram Orthopaedics	N/A	7.00	7.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASXC Asensus Surgical	9.35%
INO Inovio Pharmaceuticals	26.79%
KRMD KORU Medical Systems	58.60%
MGRM Monogram Orthopaedics	0.45%

Insider Ownership

Company	Insider Ownership
ASXC Asensus Surgical	2.87%
INO Inovio Pharmaceuticals	2.30%
KRMD KORU Medical Systems	20.60%
MGRM Monogram Orthopaedics	28.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASXC Asensus Surgical	170	272.33 million	264.52 million	Not Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
KRMD KORU Medical Systems	80	46.14 million	36.64 million	Optionable
MGRM Monogram Orthopaedics	28	35.69 million	25.66 million	Not Optionable

ASXC, INO, MGRM, and KRMD Headlines

Recent News About These Companies

Head-To-Head Comparison: Monogram Orthopaedics (NASDAQ:MGRM) & AngioDynamics (NASDAQ:ANGO)

June 17 at 2:25 AM | americanbankingnews.com

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Decrease in Short Interest

June 5, 2025 | marketbeat.com

Earnings call transcript: Monogram Orthopaedics sees stock surge after Q1 2025 results

May 16, 2025 | investing.com

Monogram Technologies Inc. (MGRM) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

A Look Ahead: Monogram Technologies's Earnings Forecast

May 16, 2025 | benzinga.com

Monogram Technologies Inc.: Monogram Technologies Reports First Quarter 2025 Financial Results

May 15, 2025 | finanznachrichten.de

Monogram Tech Gets FDA Clearance for Total Knee Arthroplasty System

May 15, 2025 | marketwatch.com

Monogram Technologies Reports First Quarter 2025 Financial Results

May 14, 2025 | globenewswire.com

Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time

May 6, 2025 | accessnewswire.com

CORRECTION FROM SOURCE: Monogram Technologies Receives Regulatory Approval to Start Clinical Trials in India

April 29, 2025 | accessnewswire.com

Monogram Technologies Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation in India

April 29, 2025 | accessnewswire.com

Monogram Orthopaedics Inc (MGRM) Receives a Rating Update from a Top Analyst

April 16, 2025 | markets.businessinsider.com

Why Monogram Technologies Inc.’s (MGRM) Stock Is Down 10.69%

March 25, 2025 | aaii.com

MGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System.

March 20, 2025 | msn.com

Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community

March 20, 2025 | accessnewswire.com

Monogram Orthopaedics price target raised to $5.40 from $4 at Roth MKM

March 18, 2025 | markets.businessinsider.com

Monogram Orthopaedics announces 510(k) clearance for mBos TKA System

March 17, 2025 | markets.businessinsider.com

FDA clears robotic knee surgery system from Monogram Technologies

March 17, 2025 | massdevice.com

Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System

March 17, 2025 | accessnewswire.com

Analysts Offer Insights on Healthcare Companies: Monogram Orthopaedics Inc (MGRM) and Vivani Medical (VANI)

March 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASXC, INO, MGRM, and KRMD Company Descriptions

Asensus Surgical NYSEAMERICAN:ASXC

$0.35 0.00 (0.00%)

As of 08/22/2024

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Inovio Pharmaceuticals NASDAQ:INO

$1.95 +0.05 (+2.63%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.03%)

As of 06/18/2025 07:51 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

KORU Medical Systems NASDAQ:KRMD

$3.25 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.25 0.00 (0.00%)

As of 06/18/2025 04:04 PM Eastern

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

Monogram Orthopaedics NASDAQ:MGRM

$2.93 +0.05 (+1.74%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.97 +0.04 (+1.37%)

As of 06/18/2025 06:40 PM Eastern

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time